Drug intelligence / Profile preview

SNA028

Development stage: Phase 1
Lead developer: SmartNuclide
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**SNA028** is a SmartNuclide two-step, GPA33-directed pretargeted radioimmunotherapy regimen for **GPA33-positive advanced colorectal cancer**. It administers the tumor-localizing agent GPA33-CC first, followed after a clearance interval by the lutetium-177 radioligand 177Lu-SmartD2, aiming to concentrate beta-emitting radiation at GPA33-expressing tumor tissue while limiting normal-tissue radiation exposure. The registered first-in-human study evaluates safety, pharmacokinetics, radiation dosimetry, tolerability, and preliminary antitumor activity.

Other names: GPA33-CC + 177Lu-SmartD2GPA33-CC;177Lu-SmartD2

Targets

177Lu-DOTA-hapten (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-lutetium-177 complex)GPA33 (Glycoprotein A33)

Beyond the preview

Go deeper on SNA028.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SNA028.

Explore the full profile